Patients that have been diagnosed their treatment options will be bases on the

Patients that have been diagnosed their treatment

This preview shows page 4 - 6 out of 6 pages.

breast cancer. Patients that have been diagnosed their treatment options will be bases on the progression of their cancer and size of tumors involved. For example, patient’s with metastatic breast cancer that is caught early have better life expectancy than those living with triple strands of breast cancer (Farrell, Harmer, Foulkes, & Allum.,2014). It is globally known that many cancers involve removal of the cancered area along with chemotherapy or radiation therapy and at times both. They days people are living longer with cancers because of the oral therapies that have been established. For example, one medical regimen in oral vinorelbine which has be authorized as treatment for state 3 or 4 lung cancer and 3 or 4 metastatic breast cancer. It is considered an alkaloid that works of the microtubulin with the cancer cell and blocks its mitosis. Blocking the cells mitosis ultimately causes the cell to die and prevents new ones to be made
Image of page 4
CANCER IN WOMEN 5 (Farrell, Harmer, Foulkes, & Allum.,2014). This medication has to be used carefully in patients that hepatic and renal impaired since it is excreted via the renal system and metabolized in the liver. Patients whose tumor cancers have been tied to specific genes can be placed on medications that are specific to the genetic make-up. For example, Vitrakvi (Larotrectinib) can be prescribed to patients whom diagnosed with tumors having abnormal NTRK genes and to whom the risk of spreading is high if the tumor is surgically removed, or the cancer is spreading despite other treatments (Bayer and Loxo Oncology., 2018). Patients need to be watched closely for neurological changes such as numbness, dizziness and loss of speech. Also, those that are hepatically impaired should not be placed on Vitrakvi. Doses of the medication is bases on the patients age and size of the tumor. Doses range from 25mg-100mg and can be administered in both capsule and liquid form usually given in two doses daily (Bayer and Loxo Oncology., 2018).
Image of page 5
Image of page 6

You've reached the end of your free preview.

Want to read all 6 pages?

  • Summer '15

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture